Search results
Results from the WOW.Com Content Network
Apraclonidine , also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α 2 adrenergic receptor agonist and a weak α 1 adrenergic receptor agonist. [ citation needed ]
The most important factor that must be taken into account when designing any type of drug delivery device, and specifically ocular devices, is the release rate of a drug. As discussed previously, the deliver rate and kinetics associated with drugs to the eye can reach levels that are toxic to the eye or could even cause undesirable side effects.
In studies comparing the effectiveness of olopatadine to alcaftadine, there was not a dose-response increase of adverse effects as alcaftadine doses increases for 0.05% to 0.1% to 0.25%. The most common seen side effect of alcaftadine administration was irritation or a stinging sensation at the administration site. [5]
Side effects of dipivefrine include local eye reactions among others. Dipivefrine is a prodrug of epinephrine (adrenaline) and hence acts as a non-selective adrenergic receptor agonist . [ 5 ] It is a substituted phenethylamine and catecholamine and is an ester of epinephrine with much greater fat solubility .
The most common side effects include conjunctival hyperaemia (red eye), pain at the site where the medicine was applied, cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), pruritus (itching of the eye), erythema (reddening) and discomfort in the eye, increased lacrimation ...
Serious side effects may include allergic reactions and heart failure. [3] Use is not recommended in those with asthma, a sulfonamide allergy, or a slow heart rate. [3] [7] Dorzolamide is a carbonic anhydrase inhibitor and timolol is a beta blocker. [3] Both work by decreasing the amount of aqueous humor made by the eye. [3]
Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. [1] [2] [3] In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.
Pirenoxine (abbreviated PRX, trade name Catalin) is a medication used in the possible treatment and prevention of cataracts.. A report in the Inorganic Chemistry journal showed that in liquid solutions, pirenoxine could cause decreased cloudiness of a crystallin solution produced to mimic the environment of the eye.